Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fascia lata membrane is a novel allogenic-derived acellular matrix produced from human fascia lata allograft. Developed for use in periodontal and implant dentistry, it serves as a biological scaffold to enhance the periodontal phenotype around dental implants. Specifically, it is used to augment the thickness and width of keratinized tissue and labial bone thickness. By providing a structural framework for cellular infiltration and tissue remodeling, it acts as an alternative to autogenous subepithelial connective tissue grafts (SCTG), thereby eliminating the need for a secondary donor site and reducing patient morbidity. It is currently being evaluated in clinical trials by Kafrelsheikh University, often in combination with platelet-rich fibrin (PRF) to optimize soft tissue healing and integration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fascia lata membrane.